Figure 6
Figure 6. Induction of APOBEC3G by CCR6 ligands. Resting or activated (A) PBMCs and (B) CD4+ T cells treated with hBD2 (20 μg/mL), hBD3 (20 μg/mL), MIP-3α (5 μg/mL), or HNP1 (5 μg/mL). (C) JKT-FT7 (CCR6low/no) and JKT-FT7 CCR6 GFP cells treated with hBD2 (20 μg/mL) or MIP-3α (5 μg/mL) for 4 hours or pretreated with 500 ng/mL PTx. (D) PBMCs treated with hBD2 (20 μg/mL) or MIP-3α (5 μg/mL) for 24 hours or pretreated with 500 ng/mL PTx. APOBEC3G and β-actin were detected at the indicated time points by Western blotting.

Induction of APOBEC3G by CCR6 ligands. Resting or activated (A) PBMCs and (B) CD4+ T cells treated with hBD2 (20 μg/mL), hBD3 (20 μg/mL), MIP-3α (5 μg/mL), or HNP1 (5 μg/mL). (C) JKT-FT7 (CCR6low/no) and JKT-FT7 CCR6 GFP cells treated with hBD2 (20 μg/mL) or MIP-3α (5 μg/mL) for 4 hours or pretreated with 500 ng/mL PTx. (D) PBMCs treated with hBD2 (20 μg/mL) or MIP-3α (5 μg/mL) for 24 hours or pretreated with 500 ng/mL PTx. APOBEC3G and β-actin were detected at the indicated time points by Western blotting.

Close Modal

or Create an Account

Close Modal
Close Modal